University of Michigan Health Systems
University of Michigan Health Systems
Ann Arbor, Michigan, United States3 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC) | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Recruiting | Phase 1 | 2026-09-23 | NCT07140016 | |
| Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer | Carcinoma, Medullary, Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Ductal, Lobular, and Medullary, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Thyroid Cancer, Papillary, adenocarcinoma, carcinoma, endocrine system disorder, epithelial neoplasm, malignant endocrine neoplasm, medullary thyroid gland carcinoma, neoplasm, neuroendocrine carcinoma, neuroendocrine neoplasm, papillary adenocarcinoma, poorly differentiated thyroid gland carcinoma, primitive neuroectodermal tumor, thyroid cancer, thyroid gland disorder, thyroid gland papillary carcinoma, thyroid gland squamous cell carcinoma, thyroid gland undifferentiated (anaplastic) carcinoma, thyroid tumor | Active, not recruiting | Phase 2 | 2026-05-20 | NCT04759911 | |
| RESPONDER-HF Trial | cardiovascular disorder, diastolic heart failure, heart disorder, heart failure | Active, not recruiting | Not applicable | 2026-03-18 | NCT05425459 |